游戏里的战斗激情,免费无码毛片一区二区A片小说 ,忍着娇喘人妻被中出中文字幕,中文字幕在线亚洲二区

美國PDS Biotechnology  
PDS Biotechnology Corporation 是一家非上市生物技術(shù)公司，致力于通過利用帶陽電荷的特殊合成脂質(zhì)中新發(fā)現(xiàn)的屬性來推廣新一代免疫療法和疫苗。專有的 Versamune? 平臺納米技術(shù)，一旦與具體癌癥相關(guān)的分子相結(jié)合，經(jīng)證實與臨床前癌癥模式中的領(lǐng)先臨床輔助治療相比，可實現(xiàn)更高的腫瘤衰退率（Cancer Immunology Immunotherapy, 2008, 57: (4) 517-530）。Versamune? 納米技術(shù)在開發(fā)新一代免疫療法方面實現(xiàn)了巨大了進步。PDS Biotechnology Corporation 正在開發(fā)治療子宮癌、頭頸癌和黑瘤等多發(fā)癌癥的主打產(chǎn)品。該技術(shù)還被用于開發(fā)預(yù)防流行病的疫苗。

PDS Biotechnology Corporation is a privately held biotechnology company founded to exploit the newly discovered properties of specific synthetic positively charged (cationic) lipids to commercialize a new generation of immunotherapies and vaccines. The proprietary Versamune? platform nanotechnology, when combined with specific cancer-associated molecules, has been demonstrated to lead to increased tumor regression rates compared to leading clinical adjuvants in pre-clinical cancer models (Cancer Immunology Immunotherapy, 2008, 57: (4) 517-530). The Versamune? nanotechnology presents a giant step forward in the development of the next generation of immunotherapies. PDS Biotechnology Corporation's lead products are being developed to treat prevalent cancers such as cervical cancer, head and neck cancer and melanoma. The technology is also being applied to the development of vaccines which are designed to protect against pandemic diseases.